SEC Form 4 · accession 0001387131-19-001528
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Seth Lederman
Officer — Chief Executive Officer · Director
Period of report
Feb 26, 2019
Accepted (ET)
Feb 27, 2019 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $1.89 | Feb 26, 2019 | A | 23,265 | A | Feb 26, 2020 | Feb 25, 2029 | Common Stock | 23,265 | 23,265 | D |
| Stock OptionF2,F1 | $2.36 | Feb 26, 2019 | A | 23,265 | A | Feb 26, 2020 | Feb 25, 2029 | Common Stock | 23,265 | 23,265 | D |
Explanation of responses
- F1The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan.